Clinical Trials Browser

INDUSTRY × Melanoma × urelumab × Clear all

NCT00612664 2015-10-12

Phase II, 2nd Line Melanoma - RAND Monotherapy

Phase 2 Completed

Melanoma

NCT00803374 2011-11-21

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

Phase 1 Withdrawn

Melanoma